13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001822947
Total reported value
$113.1M
$113.1M
22 檔
81.3%
According to the latest 13F quarterly dataset, Ally Bridge Group managed an equity portfolio of $113.1M at the end of Q3 2025, spanning 22 distinct U.S. exchange-listed positions.
In Q3 2025, Ally Bridge Group adopted a defensive or profit-taking posture, trimming 3 positions and completely liquidating 20 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 22.74% | -10.82% | EXIT | |
| 2 | REPL | Replimune Group Inc | Stock-Other | 9.19% | -1.53% | EXIT | |
| 3 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 9.12% | — | — | |
| 4 | CMPS | Compass Pathways PLC | Stock-Other | 7.58% | -4.67% | EXIT | |
| 5 | ATAI | AtaiBeckley Inc. | Stock-Other | 7.37% | — | — | |
| 6 | ASND | Ascendis Pharma A/S | Stock-Other | 6.18% | — | — | |
| 7 | LENZ | Lenz Therapeutics Inc | Stock-Other | 4.97% | — | -48.92% | |
| 8 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 3.78% | — | — | |
| 9 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 3.62% | — | — | |
| 10 | EPRX | Eupraxia Pharmaceuticals Inc | Stock-Other | 3.29% | -2.39% | — | |
| 11 | PRAX | Praxis Precision Medicines I | Stock-Other | 3.23% | -8.54% | EXIT | |
| 12 | MNPR | Monopar Therapeutics Inc | Stock-Other | 3.21% | — | +86.63% | |
| 13 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 2.68% | — | — | |
| 14 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 2.60% | — | -50.23% | |
| 15 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 2.56% | -4.58% | EXIT | |
| 16 | SLDB | Solid Biosciences Inc | Stock-Other | 2.06% | -2.20% | -24.15% | |
| 17 | PMNEUR | Promis Neurosciences Inc | Stock-Other | 1.61% | — | +367.13% | |
| 18 | AVTX | Avalo Therapeutics Inc | Stock-Other | 1.38% | +2.45% | NEW | |
| 19 | TECX | Tectonic Therapeutic Inc | Stock-Other | 1.32% | — | -15.33% | |
| 20 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 0.95% | +1.03% | — | |
| 21 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.30% | — | — | |
| 22 | ATYR | Atyr Pharma Inc | Stock-Other | 0.26% | — | +108.54% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | SLNOEUR | Soleno Therapeutics Inc | +15% | +208.96% | Add |
| 2 | PMNEUR | Promis Neurosciences Inc | +0.7% | +367.13% | Add |
| 3 | BRD1EUR | Mind Medicine Mindmed Inc | +0.5% | -50.23% | Trim |
| 4 | PRAX | Praxis Precision Medicines I | 0% | +23.64% | Add |
| 5 | WHWK | Whitehawk Therapeutics Inc | -0.4% | — | Unchanged |
| 6 | TECX | Tectonic Therapeutic Inc | -0.8% | -15.33% | Add |
| 7 | ATYR | Atyr Pharma Inc | -1.9% | +108.54% | Trim |
| 8 | TARS | Tarsus Pharmaceuticals Inc | -3.4% | -41.59% | Trim |
| 9 | REPL | Replimune Group Inc | — | NEW | New buy |
| 10 | MDGL | Madrigal Pharmaceuticals Inc | — | NEW | New buy |
| 11 | CMPS | Compass Pathways PLC | — | NEW | New buy |
| 12 | SWTXUSD | Springworks Therapeutics Inc | — | EXIT | Sold out |
| 13 | ATAI | AtaiBeckley Inc. | — | NEW | New buy |
| 14 | ASND | Ascendis Pharma A/S | — | NEW | New buy |
| 15 | VRNA | Verona Pharma PLC - Adr | — | EXIT | Sold out |
| 16 | AXSM | Axsome Therapeutics Inc | — | EXIT | Sold out |
| 17 | LENZ | Lenz Therapeutics Inc | — | NEW | New buy |
| 18 | 2655787D | Blueprint Medicines CORP | — | EXIT | Sold out |
| 19 | INSM | Insmed Inc | — | EXIT | Sold out |
| 20 | TSHA | Taysha Gene Therapies Inc | — | NEW | New buy |
| 21 | AMLX | Amylyx Pharmaceuticals Inc | — | NEW | New buy |
| 22 | ✓ | Axsome Therapeutics Inc | — | EXIT | Sold out |
| 23 | EPRX | Eupraxia Pharmaceuticals Inc | — | NEW | New buy |
| 24 | MNPR | Monopar Therapeutics Inc | — | NEW | New buy |
| 25 | ARQT | Arcutis Biotherapeutics Inc | — | NEW | New buy |
| 26 | TRVI | Trevi Therapeutics Inc | — | EXIT | Sold out |
| 27 | 260 | Centessa Pharmaceuticals-adr | — | EXIT | Sold out |
| 28 | SLDB | Solid Biosciences Inc | — | NEW | New buy |
| 29 | ELVN | Enliven Therapeutics Inc | — | EXIT | Sold out |
| 30 | ✓ | Merus N V | — | EXIT | Sold out |
| 31 | GERN | Geron CORP | — | EXIT | Sold out |
| 32 | CGON | Cg Oncology Inc | — | EXIT | Sold out |
| 33 | XENE | Xenon Pharmaceuticals Inc | — | EXIT | Sold out |
| 34 | AVTX | Avalo Therapeutics Inc | — | NEW | New buy |
| 35 | EWTX | Edgewise Therapeutics Inc | — | EXIT | Sold out |
| 36 | ✓ | Edgewise Therapeutics Inc | — | EXIT | Sold out |
| 37 | JANX | Janux Therapeutics Inc | — | EXIT | Sold out |
| 38 | DNTH | Dianthus Therapeutics Inc | — | EXIT | Sold out |
| 39 | KRRO | Korro Bio Inc | — | EXIT | Sold out |
| 40 | TYRA | Tyra Biosciences Inc | — | EXIT | Sold out |
| 41 | CNTX | Context Therapeutics Inc | — | EXIT | Sold out |
| 42 | MLTX | Moonlake Immunotherapeutics | — | NEW | New buy |
According to official SEC Form 13F filings, Ally Bridge Group reported a total U.S. public equity portfolio value of $113.1M across 22 disclosed positions in Q3 2025.
During Q3 2025, Ally Bridge Group's top holdings by market value included SLNOEUR (22.7%)、REPL (9.2%)、MDGL (9.1%). The largest single position, SLNOEUR, represented 22.7% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including SLNOEUR, REPL, MDGL) accounted for 81.3% of total reported equity market value during Q3 2025.
Top New Position Initiated
REPL
市值: $15.1M
Top Position Liquidated / Trimmed
SWTXUSD
前期市值: $12.4M
In Q3 2025, Ally Bridge Group made 41 total portfolio adjustments, initiating 14 new buys, adding to 4 positions, trimming 3 holdings, and fully liquidating 20 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.